March 21, 2019
Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.
January 9, 2019
A review by the ADDF published in Neurology® explores novel approaches beyond the common amyloid that could slow or prevent Alzheimer's.
August 2, 2018
The ADDF looks back at the 2018 Alzheimer's Association International Conference.
February 15, 2017
Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.
November 25, 2016
Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.
September 2, 2016
A treatment has reduced beta-amyloid plaques in the brains of patients with Alzheimer’s disease.
May 10, 2016
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.
July 28, 2014
Our neuroscientists share highlights from their favorite sessions at the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.
February 5, 2013
Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.
April 6, 2012
The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.